GSK 1292263

Drug Profile

GSK 1292263

Alternative Names: GSK1292263

Latest Information Update: 26 Jun 2015

Price : $50

At a glance

  • Originator GlaxoSmithKline
  • Class Antihyperglycaemics; Antihyperlipidaemics; Small molecules
  • Mechanism of Action GPR119 protein agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Discontinued Hyperlipidaemia; Type 2 diabetes mellitus

Most Recent Events

  • 11 Aug 2011 GlaxoSmithKline completes a phase II trial in Hyperlipidaemia (in combination with atorvastatin) in US (NCT01218204)
  • 23 Sep 2010 Phase-II clinical trials in Hyperlipidaemia in USA (PO)
  • 01 Mar 2010 GlaxoSmithKline completes a phase I trial in Healthy volunteers in USA
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top